Individuals with consistently positive aPL, notably those exhibiting triple positivity, face an increased risk of thrombosis and those encountering recurrent thrombotic events despite antithrombotic therapy are also at elevated risk. This evidence concerns the gene FASLG and Venous thrombosis.